ArticleNature communications2026
A versatile method for designing biosensors via regulatory domains of allosteric enzymes.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically encoded fluorescent biosensors (GEFBs) are invaluable tools for spatiotemporal metabolite monitoring in cellular metabolism, yet their development for many key metabolites is hampered by a lack of specific biorecognition elements. Here, we report a versatile strategy to engineer metabolite-responsive GEFBs by leveraging the allosteric properties of regulatory domains from allosteric enzymes. Using regulatory domains from chorismate mutase, 2-acetolactate synthase, and D-citramalate synthase as biorecognition elements, we construct three biosensors for specific L-phenylalanine, L-valine, and L-isoleucine detection. We further demonstrate that multi-ligand-binding regulatory domains can be exploited to derive diverse specific biosensors, and apply this strategy to develop two S-adenosyl-L-methionine biosensors and an S-methyl-5'-thioadenosine biosensor. We also showcase the utility of these biosensors for real-time, in situ tracking of target metabolites in living cells, as well as bioprocess monitoring and clinical diagnostics. Overall, this study establishes a flexible strategy that provides insights to construct GEFBs targeting other metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.